Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 ExpressionBusiness Wire • 06/08/22
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual MeetingBusiness Wire • 05/26/22
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 05/05/22
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?Zacks Investment Research • 04/11/22
Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 dataMarket Watch • 04/11/22
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual MeetingBusiness Wire • 04/11/22
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual MeetingBusiness Wire • 04/08/22
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual MeetingBusiness Wire • 04/07/22
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/06/22
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual MeetingBusiness Wire • 03/08/22
Bicycle Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare ConferenceBusiness Wire • 03/08/22
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 03/01/22
Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare ConferenceBusiness Wire • 02/09/22
12 biotech stocks to consider buying now as prospects for the sector brighten this yearMarket Watch • 02/06/22
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management TeamBusiness Wire • 01/05/22
Bicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is NextSeeking Alpha • 11/09/21
Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual MeetingBusiness Wire • 11/09/21
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 11/04/21
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 ExpressionBusiness Wire • 11/04/21